Biao Ma

Title: Innovations by Biao Ma in Immunotherapy

Introduction

Biao Ma is a prominent inventor based in London, GB, known for his significant contributions to the field of immunotherapy. With a total of five patents to his name, he has made remarkable strides in developing innovative treatments for various diseases.

Latest Patents

One of Biao Ma's latest patents is titled "Cytolytic immune cell comprising BCMA- and CD19-specific chimeric antigen receptors." This invention provides a chimeric antigen receptor (CAR) that binds to a low-density target antigen, which includes a Fab antigen binding domain. The invention also encompasses cells expressing such a CAR and their application in disease treatment. Another notable patent is "Molecular assessment of TRBC usage," which relates to a method for determining the T cell receptor β chain (TRBC) gene type of a cell. This method involves determining the J gene type expressed in the cell and inferring the TRBC gene type from that information. The invention further discusses the use of CAR T cells targeted to specific TRBC types and includes methods of medical treatment and nucleic acid probes.

Career Highlights

Biao Ma is currently associated with Autolus Limited, a company focused on developing innovative T cell therapies. His work at Autolus has positioned him as a key player in the advancement of CAR T cell technology, which has the potential to revolutionize cancer treatment.

Collaborations

Biao Ma collaborates with notable colleagues such as Shimobi Onuoha and Martin Pulé, contributing to a dynamic research environment that fosters innovation and discovery in immunotherapy.

Conclusion

Biao Ma's contributions to the field of immunotherapy through his patents and work at Autolus Limited highlight his role as a leading inventor in the medical research community. His innovative approaches continue to pave the way for new treatment options in the fight against diseases.